Molecular targeted therapy of head and neck cancer: Review and clinical development challenges

European Journal of Cancer

Volumn 43, Issue 17, 2007, Pages 2457-2466

  Le Tourneau, Christophe ^a   Faivre, Sandrine ^a   Siu, Lillian L ^b  

^a BEAUJON HOSPITAL   (France)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Drug development; Head and neck cancer; Review; Targeted therapy

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; AXITINIB; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; LAPATINIB; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PAZOPANIB; PEMETREXED; PERIFOSINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SERASAR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VORINOSTAT;

ARTICLE; ASTHENIA; BLEEDING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG POTENTIATION; FATIGUE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INTERSTITIAL PNEUMONIA; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RASH; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; FARNESYLTRANSTRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; NUCLEAR PROTEINS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIROLIMUS;

EID: 36048990355     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.08.016     Document Type: Article

References (104)

1. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
2. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
3. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25 (2007) 2171-2177
4. Cohen E.E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24 (2006) 2659-2665
5. Lothaire P., de Azambuja E., Dequanter D., et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28 (2006) 256-269
6. O-charoenrat P., Rhys-Evans P., Modjtahedi H., and Eccles S.A. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 18 (2000) 155-161
7. Vokes E.E., Cohen E.E., Mauer A.M., et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 23 (2005) 16s [abstr 5504]
8. .
9. Karamouzis M.V., Friedland D., Johnson R., Rajasenan K., Branstetter B., and Argiris A. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis. J Clin Oncol 25 (2007) 18s [abstr 6049]
10. Gerber H.P., and Ferrera N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 (2005) 671-680
11. Savvides P., Greskovich J., Bokar J., et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 25 (2007) 18s [abstr 6048]
12. Choong N.W., Haraf D.J., Cohen E.E., et al. Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevacizumab (FHXB) in intermediate stage head and neck cancer (HNC). J Clin Oncol 25 (2007) 18s [abstr 6034]
13. Khan A.J., King B.L., Smith B.D., et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8 (2002) 540-548
14. Gillison M.L., Glisson B.S., O'Leary E., et al. Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): response by tumor EGFR and HER2/neu status. J Clin Oncol 24 (2006) 18s [abstr 5511]
15. Ninck S., Reisser C., Dyckhoff G., Helmke B., Bauer H., and Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 106 (2003) 34-44
16. Rubin Grandis J., Melhem M.F., Barnes E.L., and Tweardy D.J. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78 (1996) 1284-1292
17. Cavalot A., Martone T., Roggero N., Brondino G., Pagano M., and Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 29 (2007) 655-664
18. Rusnak D.W., Lackey K., Affleck K., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1 (2001) 85-94
19. Abidoye O.O., Cohen E.E., Wong S.J., et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24 (2006) 18s [abstr 5568]
20. Bourhis J., Harrington K., Rosine D., et al. A phase I, open-label study (EGF100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 17 (2006) 9s [abstr 180]
21. Agus D.B., Terlizzi E., Stopfer P., Amelsberg A., and Gordon M.S. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 24 (2006) 18s [abstr 2074]
22. Mom C.H., Eskens F.A., Gietema J.A., et al. Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule. J Clin Oncol 24 (2006) 18s [abstr 3025]
23. Shaw H., Plummer R., Vidal L., et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours. J Clin Oncol 24 (2006) 18s [abstr 3027]
24. Lewis N., Marshall J., Amelsberg A., et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. J Clin Oncol 24 (2006) 18s [abstr 3091]
25. Liu L., Cao Y., Chen C., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66 (2006) 11851-11858
26. Chang Y.S., Adnane J., Trail P.A., et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59 (2007) 561-574
27. Williamson S.K., Moon J., Huang C.H., Guaglianone P., Wolf G.T., and Urba S.G. A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial. J Clin Oncol 25 (2007) 18s [abstr 6044]
28. Elser C., Siu L.L., Winquist E., et al. Phase II trial of Sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25 (2007) 3766-3773
29. .
30. .
31. .
32. .
33. Mandal M., Younes M., Swan E.A., et al. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol 42 (2006) 430-439
34. Lee J.I., Soria J.C., Hassan K.A., et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 127 (2001) 1441-1445
35. Massarelli E., Liu D.D., Lee J.J., et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104 (2005) 2430-2436
36. Argiris A., Cohen E., Karrison T., et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 5 (2006) 766-770
37. Janmaat M.L., Kruyt F.A., Rodriguez J.A., and Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9 (2003) 2316-2326
38. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
39. Aissat N., Le Tourneau C., Ghoul A., et al. Antiproliferative effects of mTOR inhibition with rapamycin (RAP) either given as a single agent or in combination with carboplatin and paclitaxel in Human Head and Neck Squamous Carcinoma Cells (HNSCC). Clin Cancer Res 25 (2007) 19s [abstr 4779]
40. Amornphimoltham P., Patel V., Sodhi A., et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65 (2005) 9953-9961
41. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336-2347
42. Buck E., Eyzaguirre A., Brown E., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small cell lung, pancomplete responseeatic, colon, and breast tumors. Mol Cancer Ther 5 (2006) 2676-2684
43. Appels N., Beijnen J., and Schellens J. Development of farnesyl transferase inhibitors: a review. The Oncologist 10 (2005) 565-578
44. Oh S.H., Kim W.Y., Kim J.H., et al. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 12 (2006) 653-661
45. Yang C.H., Kies M.S., Glisson B., et al. A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 23 (2005) 16s [abstr 5565]
46. Mantha A.J., McFee K.E., Niknejad N., Goss G., Lorimer I.A., and Dimitroulakos J. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 129 (2003) 631-641
47. Siesser P.M., and Hanks S.K. The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 12 (2006) 3233-3237
48. Johnson F.M., Saigal B., Talpaz M., and Donato M.J. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11 (2005) 6924-6932
49. Canel M., Secades P., Rodrigo J.P., et al. Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res 12 (2006) 3272-3279
50. Tabernero J., Cervantes A., Hoekman K., et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. J Clin Oncol 25 (2007) 18s [abstr 3520]
51. Siu L.L., Burris H.A., Mileshkin N., et al. Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors. J Clin Oncol 25 (2007) 18s [abstr 3527]
52. Russo S.M., Tepper J.E., Baldwin A.S., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50 (2001) 183-193
53. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7 (2001) 1419-1428
54. Van Waes C., Chang A.A., Lebowitz P.F., et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63 (2005) 1400-1412
55. Conley B.A., Donovan E., Muir C., et al. Proteasome inhibitor bortezomib & re-irradiation (rRT) with scheduled treatment break in patients (pts) with head/neck squamous carcinoma (HNSCC). J Clin Oncol 23 (2005) 16s [abstr 5592]
56. .
57. .
58. Teicher B.A. Protein kinase C as therapeutic target. Clin Cancer Res 12 (2006) 5336-5345
59. Hoffmann T.K., Leenen K., Hafner D., et al. Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines. Anticancer Drugs 13 (2002) 93-100
60. Chmura S.J., Dolan M.E., Cha A., Mauceri H.J., Kufe D.W., and Weichselbaum R.R. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res 6 (2000) 737-742
61. Propper D.J., McDonald A.C., Man A., et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 19 (2001) 1485-1492
62. Carducci M.A., Musib L., Kies M.S., et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24 (2006) 4092-4099
63. Cohen E.E., Lingen M.W., Zhu B., et al. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res 66 (2006) 6296-6303
64. Warner S.L., Gray P.J., and Von Hoff D.D. Tubulin-associated drug targets: aurora kinases, Polo-like kinases, and others. Semin Oncol 33 (2006) 436-448
65. Reiter R., Gais P., Jutting U., et al. Aurora kinase a messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 12 (2006) 5136-5141
66. Schellens J.H., Boss D., Witteveen P.O., et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. J Clin Oncol 24 (2006) 18s [abstr 3008]
67. Rubin E.H., Shapiro G.I., Stein M.N., et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J Clin Oncol 24 (2006) 18s [abstr 3009]
68. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24 (2006) 1770-1783
69. Patel V., Senderowicz A.M., Pinto D., et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 102 (1998) 1674-1681
70. Tan A.R., Headlee D., Messmann R., et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20 (2002) 4074-4082
71. Senderowicz A.M., Headlee D., Stinson S.F., et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16 (1998) 2986-2999
72. Thomas J.P., Tutsch K.D., Cleary J.F., et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50 (2002) 465-472
73. Mihara M., Shintani S., Kiyota A., Matsumura T., and Wong D.T. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int J Oncol 21 (2002) 95-101
74. Benson C., White J., De Bono J., et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96 (2007) 29-37
75. Pierga J.Y., Faivre S., Vera K., et al. A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor in patients with advanced solid tumors. J Clin Oncol 21 (2003) 15s [abstr 840]
76. Jones S.F., Burris H.A., Kies M., et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. J Clin Oncol 21 (2003) 15s [abstr 798]
77. Shapiro G.I., Lewis N., Bai S., et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-380732 with a 24-hr infusion given every three weeks in patients with metastatic refractory solid tumors. J Clin Oncol 21 (2003) 15s [abstr 799]
78. McCormick J., Gadgeel S.M., Helmke W., et al. Phase I study of BMS-387032, a cyclin dependent kinase (CDK)2 inhibitor. J Clin Oncol 22 (2003) 15s [abstr 835]
79. Patel V., Lahusen T., Leethanakul C., et al. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res 8 (2002) 3549-3560
80. Dees E.C., Baker S.D., O'Reilly S., et al. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res 11 (2005) 664-671
81. Sausville E.A., Arbuck S.G., Messmann R., et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19 (2001) 2319-2333
82. Ouaissi M., and Ouaissi A. Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotechnol 2 (2006) 1-10
83. Ondrey F.G., Dong G., Sunwoo J., et al. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 26 (1999) 119-129
84. Marks P.A., Rifkind R.A., Richon V.M., and Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 7 (2001) 759-760
85. Zhang Y., Jung M., Dritscilo A., and Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161 (2004) 667-674
86. Kelly W.K., O'Connor O.A., Krug L.M., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923-3931
87. Kelly W.K., Richon V.M., O'Connor O., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9 (2003) 3578-3588
88. Steele N., Vidal L., Plumb J., et al. A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours. J Clin Oncol 23 (2005) 16s [abstr 3035]
89. Giles F., Fischer T., Cortes J., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12 (2006) 4628-4635
90. Marshall J.L., Rizvi N., Kauh J., et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2 (2002) 325-332
91. Sandor V., Bakke S., Robey R.W., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8 (2002) 718-728
92. Gore L., Holden S.N., Basche M., et al. Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors. J Clin Oncol 22 (2004) 14s [abstr 3026]
93. Ryan Q.C., Headlee D., Acharya M., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23 (2005) 3912-3922
94. Blumenschein G., Lu C., Kies M., et al. Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer (SCCHN). J Clin Oncol 22 (2004) 14s [abstr 5578]
95. Tang P., Oza A., Townsley C., et al. A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors. J Clin Oncol 25 (2007) 18s [abstr 3576]
96. Lane H.A., and Nigg E.A. Cell-cycle control: polo-like kinases join the outer circle. Cell Biol 7 (1997) 63-68
97. Knecht R., Elez R., Oechler M., Solbach C., von Ilberg C., and Strebhardt K. Prognostic significance of polo-like kinase expression in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 2794-2797
98. Hofheinz R., Hochhaus A., Al-Batran S., et al. A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours. J Clin Oncol 24 (2006) 18s [abstr 2038]
99. Munzert G., Steinbild S., Frost A., et al. A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. J Clin Oncol 24 (2006) 18s [abstr 3069]
100. Garland L.L., Taylor C., Pilkington D.L., Cohen J.L., and Von Hoff D.D. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 12 (2006) 5182-5189
101. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24 (2006) 3354-3360
102. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5578-5587
103. Vermorken J., Mesia R., Vega V., et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - results of a randomized phase III (Extreme) study. J Clin Oncol 25 (2007) 18s
104. Gibson M.K., Li Y., Murphy B., et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 3562-3567